ENTA does not receive a milestone payment from ABBV for Maviret approval in Canada, but they do get a $15M milestone payment from ABBV for approval in Japan, which is expected in the next two quarters.
*Note spelling, which is the same as the brand name in the EU but differs from the “Mavyret” brand name in the US.